It’s National Diabetes Week 2014. BIVDA will be raising the profile of diabetes, and the importance of IVDs, in our blog and TestingTuesday Tweets. You can see all of our tweets on storify here.
Social Media has been cooking up a storm for awareness week as well, with a huge concentration written about the launch of the British Medical Journal's report on pre-diabetes diagnoses in the UK.
Using data taken from the Health Survey for England (HSE) in from 2003 - 2011, the authors have put forward the following stats:
· In 2003, 11.6% of adults surveyed had pre-diabetes,
· By 2011, the figures trebled to 35.3%
· By 2011, 50.6% of the population who were overweight (body mass index (BMI)>25) and ≥40 years of age had prediabetes
· The that socioeconomically deprived are at substantial risk.
The Article concludes that “In the absence of concerted and effective efforts to reduce risk, the number of people with diabetes is likely to increase steeply in coming years”. Early diagnosis and prevention strategies are crucial to avert the risk.
As a consequence of the report’s release, a number of news articles have sprung up:
· One in three adults in England 'on cusp' of diabetes BBC
· A third of adults have 'borderline' diabetes - but most don't know The Daily Mail
· Study reveals sharp rise in English people at risk of getting type 2 diabetes The Guardian
· One in three adults have borderline diabetes, study finds The Telegraph
Testing is essential to obtain a diagnosis. Diabetes is diagnosed by measuring the glucose in blood (or more correctly in plasma which is the fluid left behind when cells have been removed from blood) in accordance with the criteria of the World Health Organisation. Any one of the following tests are used for diagnosis:
· An HbA1c test, also called the glycohaemoglobin test
· a fasting plasma glucose (FPG) test
· an oral glucose tolerance test (OGTT)
BIVDA members have outlined some of their testing kits in our technology briefs. These illustrate cost savings and patient benefits that may be realised from appropriate deployment of in-vitro diagnostics tests.